IN2014DN06989A - - Google Patents

Info

Publication number
IN2014DN06989A
IN2014DN06989A IN6989DEN2014A IN2014DN06989A IN 2014DN06989 A IN2014DN06989 A IN 2014DN06989A IN 6989DEN2014 A IN6989DEN2014 A IN 6989DEN2014A IN 2014DN06989 A IN2014DN06989 A IN 2014DN06989A
Authority
IN
India
Prior art keywords
eosinophilic
alkyl
macular degeneration
related macular
age related
Prior art date
Application number
Other languages
English (en)
Inventor
Michael Chadham Nivens
Thierry Bouyssou
Rolf Goeggel
Peter Seither
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN06989(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IN2014DN06989A publication Critical patent/IN2014DN06989A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Structure Of Transmissions (AREA)
IN6989DEN2014 2012-04-03 2013-04-02 IN2014DN06989A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12162937 2012-04-03
PCT/EP2013/056864 WO2013149986A1 (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors

Publications (1)

Publication Number Publication Date
IN2014DN06989A true IN2014DN06989A (enrdf_load_stackoverflow) 2015-04-10

Family

ID=48040249

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6989DEN2014 IN2014DN06989A (enrdf_load_stackoverflow) 2012-04-03 2013-04-02

Country Status (28)

Country Link
US (5) US20130261153A1 (enrdf_load_stackoverflow)
EP (3) EP3763369B1 (enrdf_load_stackoverflow)
JP (2) JP2015512432A (enrdf_load_stackoverflow)
KR (4) KR20140144200A (enrdf_load_stackoverflow)
CN (2) CN110384699A (enrdf_load_stackoverflow)
AU (1) AU2013245027B2 (enrdf_load_stackoverflow)
BR (1) BR112014023795B1 (enrdf_load_stackoverflow)
CA (1) CA2869269C (enrdf_load_stackoverflow)
CL (1) CL2014002523A1 (enrdf_load_stackoverflow)
CY (1) CY1123222T1 (enrdf_load_stackoverflow)
DK (1) DK2833884T3 (enrdf_load_stackoverflow)
EA (1) EA032263B1 (enrdf_load_stackoverflow)
ES (2) ES2811554T3 (enrdf_load_stackoverflow)
HR (1) HRP20201165T1 (enrdf_load_stackoverflow)
HU (1) HUE051648T2 (enrdf_load_stackoverflow)
IL (1) IL234262A (enrdf_load_stackoverflow)
IN (1) IN2014DN06989A (enrdf_load_stackoverflow)
LT (1) LT2833884T (enrdf_load_stackoverflow)
MX (1) MX2014011786A (enrdf_load_stackoverflow)
NZ (1) NZ628882A (enrdf_load_stackoverflow)
PH (1) PH12014502239A1 (enrdf_load_stackoverflow)
PL (1) PL2833884T3 (enrdf_load_stackoverflow)
PT (1) PT2833884T (enrdf_load_stackoverflow)
RS (1) RS60665B1 (enrdf_load_stackoverflow)
SI (1) SI2833884T1 (enrdf_load_stackoverflow)
SM (1) SMT202000499T1 (enrdf_load_stackoverflow)
WO (1) WO2013149986A1 (enrdf_load_stackoverflow)
ZA (1) ZA201406082B (enrdf_load_stackoverflow)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US11045284B2 (en) 2016-11-24 2021-06-29 Kirishima Seiko Co., Ltd. Dental brace and method for attaching dental brace
KR20190131078A (ko) * 2017-04-05 2019-11-25 알카헤스트 인코포레이티드 Ccr3-억제제를 사용한 노화 관련 장애 치료를 위한 방법 및 조성물
CA3058654A1 (en) 2017-04-05 2018-10-11 Alkahest Inc. Methods and compositions for treating retina-associated disease using ccr3-inhibitors
CA3076017A1 (en) * 2017-10-13 2019-04-18 Alkahest, Inc. Methods and compositions for treating pruritus, xerosis, and associated disease using ccr3-inhibitors
WO2019222265A1 (en) 2018-05-15 2019-11-21 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase
CN112789044A (zh) * 2018-09-26 2021-05-11 万能溶剂有限公司 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物
WO2021252647A1 (en) * 2020-06-11 2021-12-16 Alkahest Inc. Methods of improving retina-associated disease outcome using ccr3-inhibitors
US11957671B2 (en) 2021-11-01 2024-04-16 Alkahest, Inc. Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
WO2001066754A1 (en) * 2000-03-03 2001-09-13 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
WO2006083390A2 (en) * 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8778616B2 (en) * 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Also Published As

Publication number Publication date
JP2015512432A (ja) 2015-04-27
PL2833884T3 (pl) 2020-11-02
LT2833884T (lt) 2020-09-10
HRP20201165T1 (hr) 2020-12-11
WO2013149986A1 (en) 2013-10-10
US20160081998A1 (en) 2016-03-24
DK2833884T3 (da) 2020-08-10
SMT202000499T1 (it) 2020-11-10
EP3763369B1 (en) 2024-02-28
HUE051648T2 (hu) 2021-03-29
PT2833884T (pt) 2020-08-26
ES2811554T3 (es) 2021-03-12
EP4389217A2 (en) 2024-06-26
US20200375971A1 (en) 2020-12-03
AU2013245027B2 (en) 2017-10-12
KR20210063481A (ko) 2021-06-01
EP2833884B1 (en) 2020-05-20
RS60665B1 (sr) 2020-09-30
PH12014502239A1 (en) 2014-12-15
CA2869269A1 (en) 2013-10-10
CA2869269C (en) 2020-06-30
JP2018080183A (ja) 2018-05-24
BR112014023795A2 (enrdf_load_stackoverflow) 2017-06-20
BR112014023795A8 (pt) 2017-10-10
EP3763369A1 (en) 2021-01-13
US20150099783A1 (en) 2015-04-09
CN110384699A (zh) 2019-10-29
CN104220073A (zh) 2014-12-17
EP4389217A3 (en) 2024-08-28
MX2014011786A (es) 2014-12-05
KR20140144200A (ko) 2014-12-18
IL234262A (en) 2017-10-31
AU2013245027A1 (en) 2014-09-11
KR20200044988A (ko) 2020-04-29
CY1123222T1 (el) 2021-10-29
ES2987267T3 (es) 2024-11-14
EP2833884A1 (en) 2015-02-11
EA032263B1 (ru) 2019-05-31
ZA201406082B (en) 2019-01-30
KR20220132012A (ko) 2022-09-29
SI2833884T1 (sl) 2020-10-30
NZ628882A (en) 2016-05-27
US20170319567A1 (en) 2017-11-09
CL2014002523A1 (es) 2015-01-23
EA201401083A1 (ru) 2015-03-31
BR112014023795B1 (pt) 2021-09-08
US20130261153A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
IN2014DN06989A (enrdf_load_stackoverflow)
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
JO3204B1 (ar) 4- أريل-n- فنيل-5،3،1- ترايازين-2- أمينات محتوية على مجموعة سلفوكسيمين
EA201391230A1 (ru) Соединения и композиции в качестве ингибиторов trk
EA201590581A1 (ru) Соединения бис-(фторалкил)-1,4-бензодиазепинона и их пролекарства
PH12014502866A1 (en) Fungicidal heterocyclic carboxamides
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
EA201290952A1 (ru) Химические соединения
AR090292A1 (es) Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan
JO3453B1 (ar) مشتقات البنزاميد لتثبيط نشاط abl1 و abl2 و bcr-abl1
EA201590930A1 (ru) Лекарственные формы руксолитиниба с замедленным высвобождением
BR112014009717A8 (pt) derivados de 2-(fenil ou pirid-3-il)aminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson.
UA115254C2 (uk) Похідні 5-фтор-n-(піридин-2-іл)піридин-2-аміну, що містять сульфоксімінову групу
MX2014003886A (es) Composiciones farmaceuticas de n-metil-2-[3-((e) 2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]benzamida.
TN2014000210A1 (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
NZ703989A (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
MD20150075A2 (ro) Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
MD20140044A2 (ro) 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare
IN2014DN07082A (enrdf_load_stackoverflow)
AR097894A1 (es) Inhibidores terapéuticos de cdk8 o uso de los mismos
PE20151718A1 (es) Compuestos piridinilpirazoloquinolina
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы